Andrew Wei, MBBS, PhD, previews this year’s AML session starting at 3:51 pm today, September 3
Acute myeloid leukemia (AML) therapy has entered a very interesting phase with a variety of highly effective and targeted drugs completely changing the therapeutic landscape in the past five years.
This session will include talks by key opinion leaders in the use of menin-, FLT3-, IDH-, and BCL2-targeted therapies. With AML being a genetically complex and continually evolving malignancy, especially under therapeutic pressure, rapid target identification, novel multiagent combinations, measurable residual disease (MRD) monitoring, and adaptation of therapy in the face of evolving resistance have become key issues for optimizing therapeutic management in 2025. These topics will be covered by Ghayas C. Issa, MD (menin inhibitors), Alexander E. Perl, MD (FLT3 inhibitors), and Courtney D. DiNardo, MD, MSCE (IDH inhibitors).
With multiple therapeutic options now available, questions have emerged regarding the optimal scheduling of targeted therapy drugs, particularly in relation to whether the sequence of use has relevance and whether tolerability and efficacy are affected by the way targeted drugs are combined, either concomitantly or sequentially. This will form the basis for interesting debate between Naval Daver, MD, and Alice S. Mims, MD, on the topic of the best strategy for using lower-intensity AML regimens.
MRD technologies have rapidly evolved and are now being used to guide targeted preemptive interventions, alongside their traditional role in guiding prognosis. I will provide an update on the new therapeutic horizon of MRD-directed therapy.
The session will be rounded out by two future-looking discussions, one regarding the incorporation of immune-based therapies into AML therapy by David A. Sallman, MD, and the other focused on the potential for artificial intelligence to help unravel the rapidly expanding data available for risk stratification of patients with AML by Ann-Kathrin Eisfeld, MD.
Please join us later today, September 3, for what promises to be an informative, intriguing, and exciting session discussing state-of-the-art topics in the field of AML.
Andrew Wei, MBBS, PhD, is the AML session co-chair and a clinical hematologist at the Peter MacCallum Cancer Centre Melbourne in Australia.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
